Long-term survival after percutaneous irreversible electroporation of inoperable colorectal liver metastases
Received 31 July 2018
Accepted for publication 19 November 2018
Published 27 December 2018 Volume 2019:11 Pages 317—322
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Dr Ahmet Emre Eskazan
Andreas Schicho,1 Christoph Niessen,1 Michael Haimerl,1 Isabel Wiesinger,1 Christian Stroszczynski,1 Lukas P Beyer,1 Philipp Wiggermann2
1Department of Radiology, University Hospital Regensburg, Regensburg, Germany; 2Department of Radiology and Nuclear Medicine, Klinikum Braunschweig, Braunschweig, Germany
Background: For colorectal liver metastases (CRLM) that are not amenable to surgery or thermal ablation, irreversible electroporation (IRE) is a novel local treatment modality and additional option.
Methods: This study is a retrospective long-term follow-up of patients with CRLM who underwent IRE as salvage treatment.
Results: Of the 24 included patients, 18 (75.0%) were male, and the median age was 57 (range: 28–75) years. The mean time elapsed from diagnosis to IRE was 37.9±37.3 months. Mean overall survival was 26.5 months after IRE (range: 2.5–69.2 months) and 58.1 months after diagnosis (range: 14.8–180.1 months). One-, three-, and five-year survival rates after initial diagnosis were 100.0%, 79.2%, and 41.2%; after IRE, the respective survival rates were 79.1%, 25.0%, and 8.3%. There were no statistically significant differences detected in survival after IRE with respect to gender, age, T- or N-stage at the time of diagnosis, size of metastases subject to IRE, number of hepatic lesions, or time elapsed between IRE and diagnosis.
Conclusion: For nonresectable CRLM, long-term survival data emphasize the value of IRE as a new minimally invasive local therapeutic approach in multimodal palliative treatment, which is currently limited to systemic or regional therapies in this setting.
Keywords: liver metastases, survival, colorectal cancer, irreversible electroporation, long-term, salvage treatment, CRLM
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]